title: Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients.
abstract: Breast cancer is a disease of cell cycle, and the dysfunction of cell cycle checkpoints plays a vital role in the occurrence and development of breast cancer. We employed multi-gene fluorescence in situ hybridization (M-FISH) to investigate gene copy number aberrations (CNAs) of 4 genes (Rb1, CHEK2, c-Myc, CCND1) that are involved in the regulation of cell cycle, in order to analyze the impact of gene aberrations on prognosis in the young breast cancer patients. Gene copy number aberrations of these 4 genes were more frequently observed in young breast cancer patients when compared with the older group. Further, these CNAs were more frequently seen in Luminal B type, Her2 overexpression, and tiple-negative breast cancer (TNBC) type in young breast cancer patients. The variations of CCND1, Rb1, and CHEK2 were significantly correlated with poor survival in the young breast cancer patient group, while the amplification of c-Myc was not obviously correlated with poor survival in young breast cancer patients. Thus, gene copy number aberrations (CNAs) of cell cycle-regulated genes can serve as an important tool for prognosis in young breast cancer patients.
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Li
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: Jingchao
authors.initials: J
authors.lastname: Bai
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: Xiaomeng
authors.initials: X
authors.lastname: Hao
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: Yunhui
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: Xiaobei
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Beijing Union Medical College Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences; Tianjin, People's Republic of China.
authors.forename: Weiping
authors.initials: W
authors.lastname: Yuan
authors.affiliation: Beijing Union Medical College Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences; Tianjin, People's Republic of China.
authors.forename: Linping
authors.initials: L
authors.lastname: Hu
authors.affiliation: Beijing Union Medical College Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences; Tianjin, People's Republic of China.
authors.forename: Tao
authors.initials: T
authors.lastname: Cheng
authors.affiliation: Clinical Pathology Department of the Karolinska Hospital; Karolinska Institute; Solna, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Zetterberg
authors.affiliation: Department of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; Program in Cancer Biology; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA; Program in Genes and Development; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA.
authors.forename: Mong-Hong
authors.initials: MH
authors.lastname: Lee
authors.affiliation: Key Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D064447:Checkpoint Kinase 2 / Q000235:genetics; D019938:Cyclin D1 / Q000235:genetics; D005260:Female; D018628:Gene Dosage; D018816:Genes, cdc; D016259:Genes, myc; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D016160:Retinoblastoma Protein / Q000235:genetics
chemical_list: D064447:Checkpoint Kinase 2; D019938:Cyclin D1; D018719:Erb-b2 Receptor Tyrosine Kinases; D016160:Retinoblastoma Protein; C530104:CCND1 protein, human; C508053:ERBB2 protein, human; C578634:CHEK2 protein, human
keywords: CCND1; CHEK2; Rb1; breast cancer; c-Myc; survival analysis